<DOC>
	<DOCNO>NCT01445769</DOCNO>
	<brief_summary>The purpose study evaluate effect alternative dosing strategy ruxolitinib subject primary myelofibrosis ( PMF ) , post-polycythemia vera-myelofibrosis ( PPV-MF ) post essential thrombocythemia-myelofibrosis ( PET-MF ) order minimize development anemia thrombocytopenia .</brief_summary>
	<brief_title>Alternative Dosing Strategy Ruxolitinib Patients With Myelofibrosis</brief_title>
	<detailed_description>This pilot study design explore alternative dose approach purpose reduce anemia thrombocytopenia . Subjects begin dose 10 mg bid opportunity dose increase base assessment efficacy overall hematologic status define prior dose interval . Dose increase restrict patient meet criterion dose hold prior 6 week , platelet count ≥100 x 10^9/L week 12 ≥150 x 10^9/L week 18 , self-reported Patient 's Global Impression Change ( PGIC ) score 3 ( minimally improve ) 7 ( much bad ) OR subject 's palpable spleen length costal margin reduce less 40 % visit relative Baseline . Dose increase elective require . Subjects permit dose increase 5 mg BID 15 mg BID Week 12 maximum 20 mg BID Week 18 . There also protocol-required dose decrease thrombocytopenia ( platelet &lt; 100 x 10^9/L ) protocol-defined anemia ( decline hemoglobin least 2 g/dL level &lt; 8 g/dL , development transfusion dependence , 50 % increase transfusion requirement transfusion dependent subject ) .This approach assume begin low dose initial therapy might positive impact rate initial hemoglobin decline nadir decrease level JAK-mediated inhibition hematopoiesis . Specific dose modification describe minimize excursion hemoglobin level Grade 3 Grade 4 range .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Diagnosis Primary Myelofibrosis ( PMF ) , PostPolycythemia Vera Myelofibrosis ( PPVMF ) , PostEssential Thrombocythemia Myelofibrosis ( PETMF ) confirm bone marrow biopsy . Must score least 2 point Dynamic International Prognostic Scoring System ( DIPSS ) scale prognostic risk factor . Peripheral blast count &lt; 5 % Screening Baseline hematology assessment . Must discontinue drug use treat underlie myelofibrosis ( MF ) disease later Day 1 ( day prior start ruxolitinib ) . Must hemoglobin value ≥ 6.5 g/dL willing receive blood transfusion . Platelet count ≥ 100*10^9/L . Must palpable spleen . Inadequate liver bone marrow reserve , end stage renal disease dialysis , clinically significant concurrent infection require therapy , unstable cardiac function . Invasive malignancy previous 5 year ( except treat early stage carcinoma skin , completely resect intraepithelial carcinoma cervix , completely resect papillary thyroid follicular thyroid cancer ) . Splenic irradiation within 6 month prior receive first dose study medication . Life expectancy le 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Myelofibrosis</keyword>
	<keyword>Primary Myelofibrosis</keyword>
	<keyword>PMF</keyword>
	<keyword>Post-Polycythemia Vera Myelofibrosis</keyword>
	<keyword>PPV-MF</keyword>
	<keyword>Post-Essential Thrombocythemia Myelofibrosis</keyword>
	<keyword>PET-MF</keyword>
	<keyword>Open label</keyword>
	<keyword>Ruxolitinib</keyword>
	<keyword>18424</keyword>
	<keyword>Jak inhibitor</keyword>
</DOC>